Risperdal®
Risperidone
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$800+ (brand historical)
With Insurance
$30–80 (generic)
How It Works
Risperidone primarily blocks D2 dopamine and 5-HT2A serotonin receptors. Compared to quetiapine, it is more D2-selective — stronger antipsychotic effect per mg, but higher risk of movement side effects and elevated prolactin.
Why the side effects happen
Prolactin elevation (causing breast discharge, menstrual irregularities, sexual dysfunction) is directly caused by D2 blockade in the pituitary — which lacks the blood-brain barrier and is therefore affected even with low doses. Weight gain and metabolic effects are less than quetiapine or olanzapine but still significant. Movement side effects (stiffness, restlessness) correlate with degree of D2 blockade.
When Will I Feel It?
Sedation and agitation control begin within hours. Antipsychotic effect develops over 1–2 weeks. Full response at 4–6 weeks.
Sedation and agitation control. Often used for acute behavioral situations.
Positive symptoms (hallucinations, delusions) begin reducing. EPS and prolactin effects often apparent by now.
Full antipsychotic response. Assess whether dose is at minimum effective level.
Adherence Note
The $2.5 billion Risperdal verdict (2019) involved J&J marketing risperidone to children and elderly for off-label uses with undisclosed gynecomastia risk. In children, risperidone can cause permanent breast development — a risk that was hidden from families for years.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Weight gain
80%Avg 5–15 lbs in adults; 15–25 lbs in children. Monthly BMI monitoring; dietary counseling essential.
Sedation / fatigue
40%Take at bedtime if possible; may diminish over weeks; avoid driving initially.
Elevated prolactin (hyperprolactinemia)
70%Annual prolactin monitoring; leads to gynecomastia in boys and menstrual irregularities in girls.
Gynecomastia in boys (breast growth)
5%Can be permanent — J&J concealed this in clinical data. Discontinue and consult endocrinologist if breast tissue develops.
Movement disorders (EPS)
20%Tremor, stiffness, restlessness. Report immediately; dose reduction or medication adjustment needed.
Metabolic syndrome
25%Annual fasting glucose, HbA1c, and lipid panel. Diet, exercise, and weight monitoring critical.
Serious Adverse Effects
- • Tardive dyskinesia — potentially irreversible involuntary movements; annual AIMS assessment
- • Neuroleptic Malignant Syndrome (NMS) — rare but life-threatening: high fever, muscle rigidity, altered consciousness
- • BLACK BOX WARNING: Increased mortality in elderly patients with dementia — do not use for dementia-related behavioral symptoms
- • Permanent gynecomastia in boys — concealed by J&J; monitor at every visit
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Tardive dyskinesia — potentially irreversible involuntary movements; annual AIMS assessment
- Neuroleptic Malignant Syndrome (NMS) — rare but life-threatening: high fever, muscle rigidity, altered consciousness
- BLACK BOX WARNING: Increased mortality in elderly patients with dementia — do not use for dementia-related behavioral symptoms
- Permanent gynecomastia in boys — concealed by J&J; monitor at every visit
- Return of psychotic symptoms (hallucinations, delusions, disorganized thinking)
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Neonatal extrapyramidal symptoms reported. Use only if benefit clearly outweighs risk; taper or discontinue before delivery if possible.
Excreted in breast milk; infant exposure can cause sedation and movement disorders.
Risperdal raises prolactin by blocking dopamine receptors. High prolactin can further suppress estrogen — amplifying the estrogen loss that already comes with menopause. Women on risperidone who are also perimenopausal may experience greater bone density loss and worsening hormonal symptoms. Discuss the combined hormonal impact with your doctor.
FDA approved for autism irritability (5+) and schizophrenia (13+). Massive off-label use for behavioral issues. Gynecomastia (permanent breast growth in boys) was concealed. Prescribing to children requires careful risk discussion.
FDA black box: increased mortality in elderly with dementia-related psychosis. Should not be used in dementia patients for behavioral symptoms.
Significant renal impairment: start at 0.5mg twice daily; titrate slowly.
Hepatic impairment reduces risperidone clearance; reduce starting dose by 50%.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Behavioral & Natural Approaches for Conditions Risperidone is Prescribed For
Applied Behavior Analysis (ABA) achieves comparable reductions in autism-related irritability — without permanent hormonal or metabolic side effects
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Applied Behavior Analysis (ABA)
20–40 hours/week intensive
Reduces irritability and self-injury in autism comparably to risperidone in long-term studies
Omega-3 (EPA/DHA — early psychosis)
EPA 700mg + DHA 480mg/day
NEURAPRO trial: 23% vs 11% transition to psychosis — omega-3 prevented psychosis in high-risk youth
CBT for psychosis (CBTp)
16–20 sessions
Equal to antipsychotics for psychotic symptoms in some patients; reduces relapse
Sensory integration therapy (autism)
OT-guided sensory diet
Reduces sensory-driven behavioral issues without medication
Melatonin (sleep in autism)
0.5–3mg 30 min before bed
Sleep disruption drives behavioral problems in autism; melatonin significantly improves sleep and daytime behavior
Global Prescribing & Pricing
US prescribes antipsychotics to children at 6× the rate of Europe
United States
$50–120 (generic)/mo
Antipsychotics prescribed to children for behavioral issues at 6× European rate
Off-label prescribing to children with behavioral disorders common; no mandatory behavioral therapy prerequisite
Usually covered with prior auth
United Kingdom
~$15–30/mo
Child antipsychotic prescribing 6× lower than US
NICE requires specialist (child psychiatrist) initiation only; behavioral therapy mandatory first for most indications
Covered by NHS with specialist approval
France
~$12–25/mo
Very low child antipsychotic prescribing rate
Psychotherapy-first model for child behavioral disorders; antipsychotics for true psychiatric diagnoses only
Covered by Assurance Maladie with specialist initiation
Germany
~$15–35/mo
Child antipsychotic prescribing significantly lower than US
Multimodal evaluation required; behavioral and psychotherapy approaches mandatory before antipsychotic for behavioral issues
Covered by GKV with specialist evaluation
Japan
~$12–28/mo
Much lower child antipsychotic prescribing — behavioral approaches emphasized
School-based behavioral support and ABA-type interventions standard before medication; strict specialist initiation
Covered by JHIS with restrictions
Johnson & Johnson paid $2.2B in 2013 for illegally marketing Risperdal to children and elderly patients. In Europe, where behavioral therapy is the mandated first-line for childhood behavioral disorders, antipsychotic use in children is 6× lower than in the US — with equivalent or better behavioral outcomes.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Johnson & Johnson paid $2.2 billion in criminal and civil penalties in 2013 — the largest healthcare fraud settlement in US history at the time. J&J was convicted of illegally marketing Risperdal to children, elderly patients, and those with developmental disabilities. They suppressed data showing gynecomastia (permanent breast growth in boys) and paid kickbacks to physicians and nursing homes. Key researchers involved in expanding indications had significant financial ties to Janssen.
Declared Conflicts of Interest
J&J's marketing campaigns explicitly targeted nursing home patients (increased mortality — FDA black box) and children with behavioral disorders despite no FDA approval. They paid physicians through speaking fees to promote off-label use. The independent CATIE trial (NIMH-funded) found risperidone offered no meaningful advantage over older antipsychotics at far lower cost.
Key Efficacy Results
Reduces psychosis symptoms ~40%; reduces autism-related irritability and self-injury ~60%; significant metabolic and hormonal side effects especially in children
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Risperidone. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Risperidone in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| RUPP Autism Network (NIMH) | NCT00080535 | |
| Risperidone in Children with Autism | PMID:11383977 | |
| CATIE Trial (Independent) | PMID:16172203 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt antipsychotic discontinuation can cause rapid psychosis relapse, tardive dyskinesia rebound, and cholinergic rebound symptoms. In children, rebound behavioral crises can be severe. Long-term antipsychotic use requires a gradual supervised taper.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe dose reduction of no more than 10–25% every 4–6 weeks
- ·For children, research supports involving the prescribing psychiatrist and school behavioral support team
- ·Research recommends pausing dose reduction if symptoms re-emerge — the appropriate next step is reassessment, not automatically restarting
- ·Research recommends monitoring for tardive dyskinesia emergence or worsening during the stopping process
- ·Research supports ensuring behavioral and therapeutic supports are in place before and during the stopping process
- ·Published literature documents that the full stopping process for long-term use may take 6–12 months or longer
Warning Symptoms — Contact Your Doctor If You Experience:
- Return of psychotic symptoms (hallucinations, delusions, disorganized thinking)
- Severe agitation, self-injury, or aggression in autism patients
- Involuntary movements of face, tongue, or limbs (tardive dyskinesia)
- Severe insomnia or anxiety disproportionate to baseline
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Has behavioral therapy been tried first, and what were the results?
- 2.What specific target behaviors are we trying to address — and how will we measure success?
- 3.For my child: what is the plan for monitoring prolactin and checking for breast tissue development?
- 4.What is the minimum effective dose, and what is the exit plan?
- 5.Has the FDA black box warning about elderly patients and increased mortality been explained to me?
Lab Tests to Request
- Prolactin level (baseline and every 6 months)
- Fasting glucose and HbA1c
- Lipid panel
- Weight and BMI monthly
- AIMS (Abnormal Involuntary Movement Scale) — annually for tardive dyskinesia
- EKG if on QT-prolonging medications
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Risperdal®
- What is Risperdal® used for?
- Risperdal® (Risperidone) is a Atypical Antipsychotic manufactured by Janssen (J&J) / Generic. FDA-approved indications include: Schizophrenia; Bipolar I disorder (acute mania); Autism-related irritability (FDA approved 5+); Adjunct in major depression (off-label); Behavioral disorders in children (off-label — the J&J fraud).
- What are the common side effects of Risperdal®?
- Common side effects of Risperdal® include: Weight gain (80%); Sedation / fatigue (40%); Elevated prolactin (hyperprolactinemia) (70%); Gynecomastia in boys (breast growth) (5%); Movement disorders (EPS) (20%).
- How much does Risperdal® cost?
- Risperdal® list price is approximately $800+ (brand historical). With insurance it typically costs $30–80 (generic); without insurance approximately $50–120 (generic).
- Who funded the clinical trials for Risperdal®?
- Johnson & Johnson paid $2.2 billion in criminal and civil penalties in 2013 — the largest healthcare fraud settlement in US history at the time. J&J was convicted of illegally marketing Risperdal to children, elderly patients, and those with developmental disabilities. They suppressed data showing gynecomastia (permanent breast growth in boys) and paid kickbacks to physicians and nursing homes. Key researchers involved in expanding indications had significant financial ties to Janssen.
- How strong is the clinical evidence for Risperdal®?
- Key studies: RUPP Autism Network trials (NIMH-funded), multiple J&J-funded schizophrenia trials, CATIE trial (NIMH-funded independent comparison). Reduces psychosis symptoms ~40%; reduces autism-related irritability and self-injury ~60%; significant metabolic and hormonal side effects especially in children Potential conflicts of interest: J&J's marketing campaigns explicitly targeted nursing home patients (increased mortality — FDA black box) and children with behavioral disorders despite no FDA approval. They paid physicians through s.
- Are there non-drug alternatives to Risperdal®?
- Applied Behavior Analysis (ABA) achieves comparable reductions in autism-related irritability — without permanent hormonal or metabolic side effects See the Alternatives tab for full details.
Get notified when we update Risperdal®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.